Wiseman, HCQ meta analysis: 42% fewer cases [p=0.04] https://c19p.org/wiseman2
copied to clipboard
Effective post-exposure prophylaxis of Covid-19 is associated with use of hydroxychloroquine: Prospective re-analysis of a public dataset incorporating novel data
et al., medRxiv, doi:10.1101/2020.11.29.20235218 (Preprint) (meta analysis)
6th independent analysis showing efficacy from the Boulware PEP trial. This prospective analysis corrects an error in the NEJM paper where shipping delays are omitted (still not corrected).42% reduction in COVID-19 (9.6% vs. 16.5%), RR 0.58 [0.35 - 0.97], p=0.044, for the original trial 3 day specification.Currently there are
38 HCQ
for COVID-19 early treatment studies, showing 72% [54‑83%] lower mortality and 41% [28‑52%] lower hospitalization.
|
risk of case, 42.0% lower, RR 0.58, p = 0.04, <= 3 days after exposure.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Wiseman et al., 12/2/2020, preprint, 4 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.